Results of a new treatment option for the treatment of bone metastases in patients with advanced breast cancer was recently presented at the 2009 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. The treatment, denosumab, is an investigational medicine developed by Amgen. It works differently from existing bone treatments by specifically targeting a protein called RANK Ligand, which plays an important role in the formation and breakdown of bone. Denosumab significantly reduced the risk of developing multiple skeletal related events by 23 percent versus Zometa(R) in advanced breast cancer patients
SATELLITE FEEDS: Thursday, December 10th, 2009 Friday, December 11th, 2009 3:30 PM - 3:45 PM ET 3:00 AM - 3:15 AM ET AMC 3 AMC 3 C-Band C-Band Transponder 3 Transponder 3 Downlink Freq. 3760 Horizontal Downlink Freq. 3760 Horizontal Friday, December 11th, 2009 1:00 PM - 1:15 PM ET AMC 3 C-Band Transponder 3 Downlink Freq. 3760 Horizontal
NEWS: Results Show Treatment Option for Bone Metastases In Patients with Advanced Breast Cancer Superior over Standard of Care
FORMAT: B-roll and Soundbites
ADDITIONAL RESOURCES: Video, contact information and more available at: http://multivu.prnewswire.com/broadcast/41387/press.html
SOUNDBITES: * Dr. Alison Stopeck, Associate Professor of Medicine and Director of the Breast Cancer Program, Arizona Cancer Center B-ROLL INCLUDES: * Bone X-rays * Researchers Working * Still Image of Radiation Equipment * Amgen Signage
VIDEO PROVIDED BY: Amgen Inc
Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3
SOURCE Amgen Inc
http://www.amgen.com